Study guide
2.1 Controlled Substances Act & DEA Scheduling
Pennsylvania MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the PA MPJE Exam 1.2 How to Use This Study Guide
2 Federal Pharmacy Law Foundations
2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Forms, Registration & Security 2.3 Federal Food, Drug, and Cosmetic Act 2.4 HIPAA & Patient Privacy 2.5 OBRA '90, Medicare/Medicaid & DUR 2.6 DSCSA & Drug Supply Chain Integrity
3 Area 1: Licensure & Personnel (22%)
3.1 Pharmacist Licensure & the PA Board of Pharmacy 3.2 Pharmacist-in-Charge Responsibilities 3.3 Pharmacy Interns & Practical Experience 3.4 Pharmacy Technicians & Trainees (PA Registration) 3.5 License Renewal, CE & Discipline 3.6 Impaired-Pharmacist Programs & Mandatory Reporting
4 Area 2: Pharmacist Practice (33%)
4.1 Prescription Requirements & Practitioner Authority 4.2 Controlled Substance Prescribing (Federal + PA) 4.3 Refills & Authority Limitations 4.4 Drug Administration & Collaborative Practice Agreements 4.5 Patient Counseling & Documentation 4.6 Returning & Reusing Drugs 4.7 Immunizations, Naloxone & Public Health 4.8 Patient Confidentiality & Pharmacy Records
5 Area 3: Dispensing Requirements (24%)
5.1 Legitimate Medical Purpose Verification 5.2 Prescription Transfers Between Pharmacies 5.3 Prospective DUR & the PA PDMP (ABC-MAP) 5.4 Refill Exceptions & Emergency Dispensing 5.5 Labeling of Dispensed Drugs 5.6 Packaging of Dispensed Drugs 5.7 Drugs & Conditions Prohibiting Dispensing 5.8 OTC, Behind-the-Counter & Hazardous Drugs
6 Area 4: Pharmacy Operations (21%)
6.1 Ordering, Acquisition & Distribution Records 6.2 Recordkeeping, Storage & Handling 6.3 Controlled Substance Inventories 6.4 Delivery of Drugs 6.5 Product Selection & Generic Substitution 6.6 Compounding: Sterile, Nonsterile & Hazardous 6.7 Central Fill & Centralized Prescription Processing 6.8 Pharmacy Permits, Inspections & Discipline
7 Test-Day Strategy & Final Review
7.1 When PA Law Is Stricter Than Federal Law 7.2 Test-Day Strategy & Common Traps
2.1 Controlled Substances Act & DEA Scheduling
Key Takeaways Explain This Topic AI
The federal Controlled Substances Act of 1970 (21 USC §§ 801–971) creates five schedules (I–V) based on abuse potential, accepted medical use, and dependence liability; DEA implements it under 21 CFR Parts 1300–1321.
Schedule I has no accepted medical use and cannot be prescribed or dispensed to patients; Schedules II–V may be dispensed by prescription, with CII carrying no refills and CIII–CIV allowing up to 5 refills within 6 months (federally, CV refills are as the prescriber authorizes).
Pennsylvania's parallel statute, The Controlled Substance, Drug, Device and Cosmetic Act (35 P.S. §§ 780-101 et seq.), adopts federal Schedules I–V by reference and empowers the Secretary of Health to reschedule substances to keep PA aligned with federal changes.
When PA and federal controlled-substance schedules conflict, the pharmacist must follow the stricter rule; gabapentin is a common trap because it is non-controlled in PA and federally and is not reportable to ABC-MAP (unlike some other states that schedule or monitor it).
Last updated: November 2026
Why Scheduling Drives Everything on the PA MPJE
The classification of a medication as a controlled substance drives nearly every operational rule a Pennsylvania pharmacist applies: how the drug may be ordered, prescribed, dispensed, refilled, stored, inventoried, returned, and reported. The federal framework is the Controlled Substances Act (CSA) of 1970 , codified in Title 21 United States Code (21 USC) §§ 801–971 and implemented by the Drug Enforcement Administration (DEA) under 21 CFR Parts 1300–1321 . Pennsylvania's parallel statute is The Controlled Substance, Drug, Device and Cosmetic Act , 35 P.S. §§ 780-101 et seq. (Act 64 of 1972), administered through the Department of Health and the State Board of Pharmacy. The PA MPJE does not separate federal from state questions; the candidate must apply the law that produces the stricter result. When PA is stricter (e.g., e-prescribing mandated for CII–CV since October 24, 2019; PDMP query required for opioids and benzodiazepines), PA controls. When federal is stricter, federal controls.
The Three Scheduling Criteria
The CSA assigns a substance to one of five schedules based on three statutory findings:
Abuse potential — actual or relative potential for abuse.
Accepted medical use — whether the substance has a currently accepted medical use in treatment in the United States.
Dependence liability — the degree of psychological or physiological dependence the substance may create.
The U.S. Attorney General (acting through the DEA Administrator) holds federal scheduling authority and must obtain a scientific and medical evaluation from the Secretary of Health and Human Services (HHS), conducted by the FDA; the HHS scientific and medical findings are binding on the Attorney General. In Pennsylvania, 35 P.S. § 780-104 authorizes the Secretary of Health (coordinating with the Department of Drug and Alcohol Programs) to add, delete, or reschedule substances to keep Pennsylvania aligned with federal scheduling.
The Five Schedules: Criteria and Examples
- Schedule Accepted Medical Use Abuse / Dependence Representative Examples
- CI None accepted High abuse; severe dependence Heroin, LSD, MDMA, peyote, psilocybin
CII Accepted (severe restrictions) High abuse; severe psychological/physical dependence Morphine, oxycodone, hydrocodone combination products, fentanyl, methadone, amphetamine, methylphenidate, secobarbital
CIII Accepted Moderate–low abuse; moderate physical or high psychological dependence Buprenorphine (mono-product), ketamine, anabolic steroids, codeine combinations (<90 mg codeine/dosage unit), dronabinol
CIV Accepted Low abuse; limited dependence Alprazolam, diazepam, lorazepam, tramadol, carisoprodol, modafinil
CV Accepted Lowest abuse; lowest dependence Pregabalin, diphenoxylate/atropine (Lomotil), lacosamide, cough preparations with <200 mg codeine per 100 mL
Key Per-Schedule Dispensing Rules
Schedule I — No prescriptions permitted. CI substances have no accepted medical use and may only be handled under a DEA Schedule I researcher registration. They cannot be dispensed to a patient under any circumstance, even with a prescriber order.
CII — Dispensable by prescription, no refills (21 CFR 1306.12). Two federal partial-fill carve-outs apply: (1) a pharmacist may partially fill a CII prescription if the patient cannot tolerate the full quantity or the pharmacy lacks sufficient stock, by noting the reason on the reverse of the prescription (or documenting electronically in an EPCS record), with the remainder fillable within 72 hours; and (2) a prescription for a compounded CII for direct administration to a long-term care (LTC) or terminally ill patient may be partially filled, with the remainder fillable within 72 hours. PA follows these federal partial-fill rules.
CIII–CIV — Refills up to 5 times within 6 months of the date of issue (21 CFR 1306.22); federally, CV refills are as the prescriber authorizes. After 5 refills or 6 months, whichever comes first, the prescription is void and a new prescription is required.
E-prescribing of controlled substances (EPCS) — Authorized under 21 CFR Part 1311 ; PA has mandated e-prescribing of all CII–CV controlled substances since October 24, 2019 , with limited statutory exceptions (e.g., temporary technological failure, hospice, veterinary).
Pennsylvania's Parallel Statute and How PA Aligns
35 P.S. § 780-104 adopts the federal schedules by reference and empowers the Secretary of Health to add, reschedule, or delete substances to keep PA aligned with federal changes. When the DEA reschedules a substance (e.g., hydrocodone combination products from CIII to CII in October 2014; tramadol placed in CIV in 2014; gabapentin remained non-controlled federally), PA's schedule moves in lockstep through state regulatory action. PA also layers state-specific monitoring on top of federal scheduling:
Gabapentin — Not federally scheduled and not in PA Schedules I–V. Pennsylvania does not require gabapentin dispensing to be reported to ABC-MAP (reporting is limited to Schedules II–V controlled substances). Some other states schedule gabapentin or mandate PDMP reporting — that is not PA law.
Ephedrine and pseudoephedrine — Tracked under federal Combat Methamphetamine Epidemic Act (CMEA) limits and PA precursor chemical rules; PA enforces daily and 30-day purchase limits and tracks sales.
Naloxone — Non-controlled; PA's Act 139 of 2014 (David's Law) authorizes dispensing under a standing order issued by the PA Secretary of Health / Physician General, without an individual prescription.
Common MPJE Scheduling Traps
The "Schedule I prescription" question — Any answer suggesting a CI may be dispensed on a prescription is wrong. CI = no accepted medical use, no prescribing.
The gabapentin trap — Federally non-controlled and not Schedule V in PA, and not ABC-MAP-reportable. A question asking about gabapentin should not apply Schedule V handling or PDMP reporting rules; contrast with states that do schedule or monitor gabapentin.
CII refills — A CII prescription cannot be refilled under ordinary circumstances; the only federal carve-out is the LTC/terminally-ill compound-for-direct-administration partial fill.
Hydrocodone combination products (HCPs) — Schedule II federally and in PA since October 6, 2014. Any answer describing HCPs as Schedule III reflects a pre-2014 rule and is wrong on the 2026 exam.
Fentanyl — Schedule II; despite its high potency, it has accepted medical use, distinguishing it from Schedule I.
Dronabinol (synthetic THC, Marinol) — Schedule III federally and in PA, while marijuana remains Schedule I federally except FDA-approved drug products and marijuana under a state medical marijuana license (Schedule III since April 28, 2026). Do not confuse the two.